Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients

Abstract Background Targeting CD3 × CD20 bispecific antibodies (BsAbs) represents a new milestone in the salvage therapy of relapsed/relapsed large B cell lymphoma and follicular lymphoma. However, cytokine release syndrome (CRS) remains one of the major concerns in clinical practice of CD3 × CD20 B...

Full description

Bibliographic Details

Published in:	Cancer Immunology, Immunotherapy
Main Authors:	Peng Sun, Cui Chen, Bai-Tian Zhao, Bo-Yan Zhang, Hang Yang, Yu Wang, Fei Xu, Kang-Ming Huang, Yin-Ting Liu, Mei-Shuo Ouyang, Jia-Jia Huang, Pan-Pan Liu, Ying Guo, Zhi-Ming Li
Format:	Article
Language:	English
Published:	Springer 2025-06-01
Subjects:	CD3 × CD20 bispecific antibodies (BsAbs) Cytokine release syndrome (CRS) Predictive factors Nomogram
Online Access:	https://doi.org/10.1007/s00262-025-04080-6